Showing results (111-120 of 183) with videos related to
Sort By:
Pageof 19
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.Antiviral Therapy|May 12, 2004
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapineMontserrat Plana, Elena Ferrer, Catalina Martínez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.Antiviral Therapy|July 19, 2012
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune functionArkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.Atherosclerosis|September 29, 2012
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudyMaria Saumoy, José Luis Sánchez-Quesada, Esteban Martínez, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 1, 2008
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter studyVicenç Falcó, Montserrat Olmo, Sara Villar del Saz, et al.Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.Antiviral Therapy|February 4, 2012
Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapyArkaitz Imaz, Montserrat Olmo, Maria Peñaranda, et al.Pageof 19